Prudential Financial Inc Kura Oncology, Inc. Transaction History

Prudential Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$17.53 - $22.98 $16,478 - $21,601	940 Added 5.42%	18,277 $376,000
Q1 2024 May 14, 2024	BUY	$13.42 - $23.53 $232,662 - $407,939	17,337 New	17,337 $369,000
Q1 2021 May 12, 2021	SELL	$24.75 - $39.14 $164,018 - $259,380	-6,627 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $192,183 - $275,815	6,627 New	6,627 $216,000
Q2 2020 Aug 12, 2020	SELL	$7.95 - $18.81 $1,979 - $4,683	-249 Closed	0 $0
Q1 2020 Aug 05, 2021	SELL	$6.45 - $14.04 $110,914 - $241,431	-17,196 Reduced 98.57%	249 $2,000
Q1 2020 May 12, 2020	BUY	$6.45 - $14.04 $110,862 - $241,319	17,188 Added 6687.94%	17,445 $173,000
Q4 2019 Aug 05, 2021	SELL	$12.97 - $15.94 $863,529 - $1.06 Million	-66,579 Reduced 99.62%	257 $4,000
Q4 2019 Feb 11, 2020	BUY	$12.97 - $15.94 $863,438 - $1.06 Million	66,572 Added 25216.67%	66,836 $918,000
Q3 2019 Aug 05, 2021	SELL	$14.75 - $20.87 $974,886 - $1.38 Million	-66,094 Reduced 99.6%	264 $4,000
Q3 2019 Nov 13, 2019	BUY	$14.75 - $20.87 $978,780 - $1.38 Million	66,358 New	66,358 $1.01 Million

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.